Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
Status:
Not yet recruiting
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human
anti-PD-1 monoclonal antibody) for patients with hepatocellular carcinoma and microvascular
invasion (MVI) after hepatectomy.